Executive Chair & Founding CEO
Karinza Phoenix
Ms Phoenix has more than 24 years of executive and commercial experience in pharmaceutical, veterinary and capital markets sectors, inclusive of holding operational and marketing roles at Pfizer, Novartis and Zoetis. Ms Phoenix has a successful track record of product development, registration and marketing launches, incorporating successful commercialisation of numerous market leading blockbuster medicines. Ms Phoenix has served on the Myopharm Board of Directors for 4 years and has invested in almost all capital raises to date, while focussing on expanding Myopharm’s clinical and commercial initiatives.
role
Executive Chair & Founding CEO
Myopharm Ltd (Pre-IPO)
As investor interest in healthcare and biotech continues to accelerate, Myopharm is positioning itself at the intersection of scientific innovation and real‑world patient impact, making this a timely and highly relevant presentation for investors seeking exposure to meaningful growth opportunities.
Myopharm is building strong momentum across its clinical and commercial programs, with several important updates expected across its pipeline and development initiatives.
View the Stocks in the Vines presentation recording to hear Myopharm’s latest strategic update:
For Karinza, the inspiration to build Myopharm came from recognising the growing impact of diabetes and the need for better treatment options for patients living with chronic disease. That insight helped drive the creation of Myopharm:
With a mission to develop innovative therapies that address significant unmet medical needs and improve patient outcomes.
At Stocks in the Vines 2026, Karinza shared with Peter Taylor the story behind Myopharm, the challenges and opportunities ahead, and why she believes innovation in healthcare has the potential to make a meaningful difference in people's lives.
Watch the full interview to hear Karinza's journey and vision for the future of Myopharm:
🚨 A must-watch interview for biotech investors. Karinza Phoenix discusses the company’s upcoming IPO and why the business is strategically positioned within one of the fastest-growing segments of global healthcare. With increasing demand for GLP-1 related therapies and growing industry interest in combination treatments,
Myopharm is targeting a market experiencing rapid expansion and significant pharmaceutical attention.
Karinza also explains how looming patent expiries across major diabetes and metabolic disease treatments could create substantial opportunities for emerging innovators, potentially reshaping the competitive landscape over the coming years.
As global healthcare markets continue evolving, Myopharm is positioning itself to capitalise on these shifts through innovation, strategic timing and a growing market need:
Myopharm Ltd (Pre-IPO)
As investor interest in healthcare and biotech continues to accelerate, Myopharm is positioning itself at the intersection of scientific innovation and real‑world patient impact, making this a timely and highly relevant presentation for investors seeking exposure to meaningful growth opportunities.
Myopharm is building strong momentum across its clinical and commercial programs, with several important updates expected across its pipeline and development initiatives.
View the Stocks in the Vines presentation recording to hear Myopharm’s latest strategic update:
For Karinza, the inspiration to build Myopharm came from recognising the growing impact of diabetes and the need for better treatment options for patients living with chronic disease. That insight helped drive the creation of Myopharm:
With a mission to develop innovative therapies that address significant unmet medical needs and improve patient outcomes.
At Stocks in the Vines 2026, Karinza shared with Peter Taylor the story behind Myopharm, the challenges and opportunities ahead, and why she believes innovation in healthcare has the potential to make a meaningful difference in people's lives.
Watch the full interview to hear Karinza's journey and vision for the future of Myopharm:
🚨 A must-watch interview for biotech investors. Karinza Phoenix discusses the company’s upcoming IPO and why the business is strategically positioned within one of the fastest-growing segments of global healthcare. With increasing demand for GLP-1 related therapies and growing industry interest in combination treatments,
Myopharm is targeting a market experiencing rapid expansion and significant pharmaceutical attention.
Karinza also explains how looming patent expiries across major diabetes and metabolic disease treatments could create substantial opportunities for emerging innovators, potentially reshaping the competitive landscape over the coming years.
As global healthcare markets continue evolving, Myopharm is positioning itself to capitalise on these shifts through innovation, strategic timing and a growing market need:
